Dodge & Cox Stock Fund Alnylam Pharmaceuticals Inc transactions over time
ALNY
Alnylam Pharmaceuticals Inc historical holders
total: 2
Transactions details
- Total transactions:
- 21
- New positions:
- 1
- Added:
- 3
- Reduced:
- 17
- Held since:
- 2019 Q3
- Held for:
- 28 quarters
- Latest activity:
- 2025 Q4
Dodge & Cox Stock Fund has been an institutional investor in Alnylam Pharmaceuticals Inc (ALNY) since 2019 Q3. According to 2026 Q2 report, Dodge & Cox Stock Fund holds 1,233,200 shares with a market value of roughly $371.23M representing 0.31% of their equity portfolio. The fund/company first acquired ALNY in 2019 Q3, initially purchasing about 3.20M shares. Since the initial investment, Dodge & Cox Stock Fund has made 20 more transactions in this position.
Does Dodge & Cox Stock Fund still hold ALNY?
Yes, Dodge & Cox Stock Fund continues to hold Alnylam Pharmaceuticals Inc (ALNY). According to their 2026 Q2 report, they maintain a position of 1,233,200 shares valued at approximately $371.23M, representing 0.31% of their equity portfolio.
When did Dodge & Cox Stock Fund first invest in ALNY?
Dodge & Cox Stock Fund first invested in Alnylam Pharmaceuticals Inc (ALNY) in 2019 Q3 at the reported quarter-end price of $80.42 per share, acquiring 3,197,761 shares in their initial purchase.
What is Dodge & Cox Stock Fund's average cost basis for ALNY?
Based on historical transaction data, Dodge & Cox Stock Fund's estimated cost basis for Alnylam Pharmaceuticals Inc (ALNY) is approximately $99.08 per share. This represents their average reported price* across all buy transactions.
Estimated cost basis*
- Weighted AVG buy price:
- $99.08
- Weighted AVG sell price:
- $259.30
ALNY transactions history by Dodge & Cox Stock Fund
21 results
| Period |
% of portfolio |
Shares held after* |
Reported price* |
Value* |
% (shares) of activity |
% change to portfolio |
|---|---|---|---|---|---|---|
|
2025 Q4
|
0.41%
|
1,233,200
|
$397.65
|
$490,381,980
|
-17.41% (-259,873)
|
-0.09%
|
|
2025 Q3
|
0.57%
|
1,493,073
|
$456.00
|
$680,841,288
|
-26.74% (-545,027)
|
-0.21%
|
|
2025 Q2
|
0.57%
|
2,038,100
|
$326.09
|
$664,604,029
|
-6.00% (-130,000)
|
-0.04%
|
|
2025 Q1
|
0.51%
|
2,168,100
|
$270.02
|
$585,430,362
|
-6.35% (-146,900)
|
-0.04%
|
|
2024 Q4
|
0.49%
|
2,315,000
|
$235.31
|
$544,742,650
|
-0.10% (-2,300)
|
-0%
|
|
2024 Q3
|
0.55%
|
2,317,300
|
$275.03
|
$637,327,019
|
-1.24% (-29,100)
|
-0.01%
|
|
2023 Q4
|
0.44%
|
2,346,400
|
$191.41
|
$449,124,424
|
-2.12% (-50,800)
|
-0.01%
|
|
2023 Q3
|
0.46%
|
2,397,200
|
$177.10
|
$424,544,120
|
-1.29% (-31,400)
|
-0.01%
|
|
2023 Q2
|
0.50%
|
2,428,600
|
$189.94
|
$461,288,284
|
+0.36% (+8,600)
|
+0%
|
|
2023 Q1
|
0.55%
|
2,420,000
|
$200.32
|
$484,774,400
|
-18.29% (-541,777)
|
-0.12%
|
|
2022 Q4
|
0.80%
|
$237.65
|
-2.68% (-81,600)
|
|||
|
2022 Q3
|
0.77%
|
$200.16
|
-1.78% (-55,000)
|
|||
|
2022 Q2
|
0.53%
|
$145.85
|
-4.64% (-150,800)
|
|||
|
2021 Q4
|
0.57%
|
$169.58
|
+4.50% (+140,000)
|
|||
|
2021 Q2
|
0.59%
|
$169.52
|
+28.84% (+695,985)
|
|||
|
2021 Q1
|
0.42%
|
$141.19
|
-8.91% (-235,969)
|
|||
|
2020 Q4
|
0.49%
|
$129.97
|
-0.16% (-4,300)
|
|||
|
2020 Q3
|
0.64%
|
$145.60
|
-4.73% (-131,800)
|
|||
|
2020 Q2
|
0.69%
|
$148.11
|
-9.72% (-300,000)
|
|||
|
2020 Q1
|
0.65%
|
$108.85
|
-3.52% (-112,500)
|
|||
|
2019 Q3
|
0.37%
|
$80.42
|
new
|
|||
* Shares, change to shares, sold shares, shares held after: split-adjusted.
* Reported price: this doesn't represent the actual buy or sell price. It is the split-adjusted price of the security as of the last day of the reported period.
If the security is completely sold out, we show the reported split-adjusted price prior to the actual period.
If the security is completely sold out, we show the reported split-adjusted price prior to the actual period.
* Estimated cost basis: based on "Reported price*" (not earlier than 2013 Q2). Calculation starts from the latest "new buy" activity to the latest "close out" activity (if any).
* Value or Price: If the security is completely sold out, we show the reported value (or price) prior to the actual period.
* New buy or own: this means there is no earlier reporting (for us or in general). So we can't know if the actual purchase of the security happened at the reported period or earlier.